Cargando…
S121: REDUCED RATE OF VASO-OCCLUSIVE CRISES (VOCS) IN PATIENTS (PTS) WITH SICKLE CELL DISEASE (SCD) TREATED WITH CRIZANLIZUMAB FOR 12 MONTHS: RESULTS FROM A REAL-WORLD, MANAGED ACCESS PROGRAM (MAP)
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812129/ http://dx.doi.org/10.1097/01.HS9.0000821452.65842.6a |
| _version_ | 1784644583173390336 |
|---|---|
| author | Silva-Pinto, A Colombatti, R Pasanisi, A Arcioni, F DeBonnett, L Soliman, W Sarkar, R Cançado, R |
| author_facet | Silva-Pinto, A Colombatti, R Pasanisi, A Arcioni, F DeBonnett, L Soliman, W Sarkar, R Cançado, R |
| author_sort | Silva-Pinto, A |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8812129 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-88121292022-02-18 S121: REDUCED RATE OF VASO-OCCLUSIVE CRISES (VOCS) IN PATIENTS (PTS) WITH SICKLE CELL DISEASE (SCD) TREATED WITH CRIZANLIZUMAB FOR 12 MONTHS: RESULTS FROM A REAL-WORLD, MANAGED ACCESS PROGRAM (MAP) Silva-Pinto, A Colombatti, R Pasanisi, A Arcioni, F DeBonnett, L Soliman, W Sarkar, R Cançado, R Hemasphere Oral Presentations Lippincott Williams & Wilkins 2022-01-31 /pmc/articles/PMC8812129/ http://dx.doi.org/10.1097/01.HS9.0000821452.65842.6a Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Oral Presentations Silva-Pinto, A Colombatti, R Pasanisi, A Arcioni, F DeBonnett, L Soliman, W Sarkar, R Cançado, R S121: REDUCED RATE OF VASO-OCCLUSIVE CRISES (VOCS) IN PATIENTS (PTS) WITH SICKLE CELL DISEASE (SCD) TREATED WITH CRIZANLIZUMAB FOR 12 MONTHS: RESULTS FROM A REAL-WORLD, MANAGED ACCESS PROGRAM (MAP) |
| title | S121: REDUCED RATE OF VASO-OCCLUSIVE CRISES (VOCS) IN PATIENTS (PTS) WITH SICKLE CELL DISEASE (SCD) TREATED WITH CRIZANLIZUMAB FOR 12 MONTHS: RESULTS FROM A REAL-WORLD, MANAGED ACCESS PROGRAM (MAP) |
| title_full | S121: REDUCED RATE OF VASO-OCCLUSIVE CRISES (VOCS) IN PATIENTS (PTS) WITH SICKLE CELL DISEASE (SCD) TREATED WITH CRIZANLIZUMAB FOR 12 MONTHS: RESULTS FROM A REAL-WORLD, MANAGED ACCESS PROGRAM (MAP) |
| title_fullStr | S121: REDUCED RATE OF VASO-OCCLUSIVE CRISES (VOCS) IN PATIENTS (PTS) WITH SICKLE CELL DISEASE (SCD) TREATED WITH CRIZANLIZUMAB FOR 12 MONTHS: RESULTS FROM A REAL-WORLD, MANAGED ACCESS PROGRAM (MAP) |
| title_full_unstemmed | S121: REDUCED RATE OF VASO-OCCLUSIVE CRISES (VOCS) IN PATIENTS (PTS) WITH SICKLE CELL DISEASE (SCD) TREATED WITH CRIZANLIZUMAB FOR 12 MONTHS: RESULTS FROM A REAL-WORLD, MANAGED ACCESS PROGRAM (MAP) |
| title_short | S121: REDUCED RATE OF VASO-OCCLUSIVE CRISES (VOCS) IN PATIENTS (PTS) WITH SICKLE CELL DISEASE (SCD) TREATED WITH CRIZANLIZUMAB FOR 12 MONTHS: RESULTS FROM A REAL-WORLD, MANAGED ACCESS PROGRAM (MAP) |
| title_sort | s121: reduced rate of vaso-occlusive crises (vocs) in patients (pts) with sickle cell disease (scd) treated with crizanlizumab for 12 months: results from a real-world, managed access program (map) |
| topic | Oral Presentations |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812129/ http://dx.doi.org/10.1097/01.HS9.0000821452.65842.6a |
| work_keys_str_mv | AT silvapintoa s121reducedrateofvasoocclusivecrisesvocsinpatientsptswithsicklecelldiseasescdtreatedwithcrizanlizumabfor12monthsresultsfromarealworldmanagedaccessprogrammap AT colombattir s121reducedrateofvasoocclusivecrisesvocsinpatientsptswithsicklecelldiseasescdtreatedwithcrizanlizumabfor12monthsresultsfromarealworldmanagedaccessprogrammap AT pasanisia s121reducedrateofvasoocclusivecrisesvocsinpatientsptswithsicklecelldiseasescdtreatedwithcrizanlizumabfor12monthsresultsfromarealworldmanagedaccessprogrammap AT arcionif s121reducedrateofvasoocclusivecrisesvocsinpatientsptswithsicklecelldiseasescdtreatedwithcrizanlizumabfor12monthsresultsfromarealworldmanagedaccessprogrammap AT debonnettl s121reducedrateofvasoocclusivecrisesvocsinpatientsptswithsicklecelldiseasescdtreatedwithcrizanlizumabfor12monthsresultsfromarealworldmanagedaccessprogrammap AT solimanw s121reducedrateofvasoocclusivecrisesvocsinpatientsptswithsicklecelldiseasescdtreatedwithcrizanlizumabfor12monthsresultsfromarealworldmanagedaccessprogrammap AT sarkarr s121reducedrateofvasoocclusivecrisesvocsinpatientsptswithsicklecelldiseasescdtreatedwithcrizanlizumabfor12monthsresultsfromarealworldmanagedaccessprogrammap AT cancador s121reducedrateofvasoocclusivecrisesvocsinpatientsptswithsicklecelldiseasescdtreatedwithcrizanlizumabfor12monthsresultsfromarealworldmanagedaccessprogrammap |